<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02074891</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-6511</org_study_id>
    <nct_id>NCT02074891</nct_id>
  </id_info>
  <brief_title>Sustainable Healthcenter Implementation PrEP Pilot Study</brief_title>
  <acronym>SHIPP</acronym>
  <official_title>Sustainable Healthcenter Implementation PrEP Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CDC Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A health services implementation pilot study, conducted with an observational cohort of
      HIV-uninfected persons including men who have sex with men,  heterosexual women and men, and
      injection drug users receiving daily oral antiretroviral preexposure prophylaxis (PrEP) at
      four federally qualified health centers that provide sexual health and primary care services
      to communities with high HIV incidence/prevalence.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Clinical safety</measure>
    <time_frame>Every 3 months up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Side effects, rates of renal adverse events, rates of atraumatic bone fractures, HIV infections with/without virus with mutations associated with TDF or FTC resistance, documented at clinical visits while prescribed PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>Every 3 months up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Self-reported medication adherence and detection of tenofovir in dried blood spots at each clinical visit while prescribed PrEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Responses</measure>
    <time_frame>Every 3 months up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Trends in sexual and injection HIV acquisition risk behaviors among patients  measured at each clinic visit while prescribed PrEP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Source of payment, cost, and reimbusement for medication and clinical care associated with each clinical visit for PrEP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical practice variation</measure>
    <time_frame>Every 3 months up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Variation in clinical practices at each clinic visit for PrEP-related care relative to PHS PrEP guidelines, and the relationship of clinical practices to patient outcomes</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>HIV Chemoprophylaxis</condition>
  <condition>HIV Preexposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Persons prescribed PrEP</arm_group_label>
    <description>adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC  to reduce HIV acquisition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>coformulated TDF/FTC</intervention_name>
    <description>Daily oral dose of coformulated TDF/FTC</description>
    <arm_group_label>Persons prescribed PrEP</arm_group_label>
    <other_name>Truvada</other_name>
    <other_name>Tenofovir disoproxil fumarate (TDF)</other_name>
    <other_name>Emtracitabine (FTC)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried blood spots
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1200 adult men who have sex with men, injection drug users, and heterosexually-active men
        and women who are at substantial risk of acquiring HIV infection and initiate the use of
        daily oral antiretroviral preexposure prophylaxis (PrEP) with TDF/FTC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult

          -  documented without HIV infection (acute or established)

          -  report sexual behaviors that indicate substantial risk of HIV acquisition

          -  report injection-related behaviors that indicate substantial risk of HIV acquisition

        Exclusion Criteria:

          -  &lt;18 years of age

          -  documented HIV infection (acute or established)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn K Smith, MD, MS, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Hartz, MPH</last_name>
    <role>Study Director</role>
    <affiliation>CDC Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dawn K Smith, MD, MS, MPH</last_name>
    <phone>404-639-5166</phone>
    <email>dsmith1@cdc.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Access Community Health Network - Grand Boulevard Health and Specialty Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milton (Mickey) Eder, PhD</last_name>
      <phone>312-526-2116</phone>
      <email>mickey.eder@accesscommunityhealth.net</email>
    </contact>
    <investigator>
      <last_name>Milton (Mickey) Eder, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Community Health Centers - Ludlow St. Clinic</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ada Emuwa, MD, MPH</last_name>
      <phone>973-565-0355</phone>
      <email>Aemuwa@nchcfqhc.org</email>
    </contact>
    <investigator>
      <last_name>Ada Emuwa, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strawberry Mansion Health Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena Kwakwa, MD, MPH</last_name>
      <phone>215-685-6769</phone>
      <email>hkwakwa@aol.com</email>
    </contact>
    <investigator>
      <last_name>Helena Kwakwa, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Care Community Health Centers - MLK Boulevard Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sumbo Adeniran, MHA</last_name>
      <phone>832-308-1084</phone>
      <email>sadeniran@centralcarechc.org</email>
    </contact>
    <investigator>
      <last_name>Sumbo Adeniran, MHA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/hiv/prevention/research/prep/</url>
    <description>Link to CDC information about preexposure prophylaxis</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 22, 2014</lastchanged_date>
  <firstreceived_date>February 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centers for Disease Control and Prevention</investigator_affiliation>
    <investigator_full_name>Dawn Smith</investigator_full_name>
    <investigator_title>Biomedical Interventions Activity Lead, Epidemiology Branch, DHAP, NCHHSTP</investigator_title>
  </responsible_party>
  <keyword>preexposure prophylaxis</keyword>
  <keyword>PrEP</keyword>
  <keyword>HIV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir disoproxil</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
